{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Moderna, Inc. technically bullish or bearish?
As of October 31, 2025, Moderna, Inc. is in a mildly bearish trend, with mixed technical indicators showing some bullish signals but overall underperformance compared to the S&P 500, including a year-to-date return of -42.88%.
Moderna Stock Hits Day Low at $24.74 Amid Price Pressure
Moderna, Inc. has faced significant stock volatility, with notable declines over various timeframes, including a year-to-date drop of 40.09%. The company reported a substantial decrease in net sales and a considerable net profit loss, compounded by rising raw material costs, indicating ongoing financial challenges.
Moderna, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
Moderna, Inc. has recently revised its evaluation amid challenging market conditions, with its stock price declining significantly over the past year. The company has faced substantial losses compared to the S&P 500, and technical indicators present mixed signals, reflecting ongoing volatility and a cautious outlook for its performance.
Is Moderna, Inc. technically bullish or bearish?
As of October 31, 2025, Moderna, Inc. is in a mildly bearish trend, with daily moving averages and weekly indicators showing weakness, despite a mildly bullish MACD and a significant underperformance of -40.09% year-to-date compared to the S&P 500's 16.30% return.
Is Moderna, Inc. technically bullish or bearish?
As of October 31, 2025, Moderna, Inc. is in a mildly bearish trend with mixed technical signals, underperforming the S&P 500 significantly year-to-date and over the past year.
Is Moderna, Inc. technically bullish or bearish?
As of October 31, 2025, Moderna, Inc. shows a mildly bearish trend with daily moving averages and weekly indicators signaling bearishness, despite some underlying strength from the MACD and monthly RSI, and has underperformed the S&P 500 with a return of -50.04% compared to its 19.89%.
Moderna Stock Soars 13.93%, Hits Intraday High of $29.20
Moderna, Inc. has seen notable stock activity today, contrasting with a flat S&P 500. Despite recent gains, the company faces significant challenges, including a sharp decline in net sales and profit losses. Additionally, raw material costs have surged, highlighting ongoing financial difficulties within the biotechnology sector.
Moderna, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
Moderna, Inc. has recently revised its evaluation amid ongoing market challenges, with its stock priced at $25.24. Over the past year, the company has experienced a significant decline, contrasting sharply with the S&P 500's performance. Technical indicators show mixed signals, reflecting underlying selling pressure.
Is Moderna, Inc. technically bullish or bearish?
As of June 24, 2025, Moderna, Inc. is in a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly year-to-date and over the past year.
Is Moderna, Inc. overvalued or undervalued?
As of November 2, 2023, Moderna, Inc. is considered overvalued with a risky valuation grade, reflected by key metrics such as a Price to Book Value of 1.05 and a -90.22% ROCE, alongside a year-to-date stock performance of -38.79%, significantly underperforming the S&P 500's 12.22% return.
Is Moderna, Inc. overvalued or undervalued?
As of November 2, 2023, Moderna, Inc. is considered overvalued and risky due to significant financial losses, reflected in a price-to-book ratio of 1.05, an EV to EBITDA of -1.33, and a return on equity of -33.35%, especially when compared to healthier peers like Amgen and Biogen, while also underperforming the S&P 500 with a year-to-date decline of 38.26%.
Is Moderna, Inc. technically bullish or bearish?
As of June 6, 2025, Moderna, Inc. shows a mildly bearish trend with mixed signals, as the weekly MACD indicates mild bullishness while the monthly MACD and moving averages remain bearish.
Who are in the management team of Moderna, Inc.?
As of March 2022, the management team of Moderna, Inc. includes Dr. Noubar Afeyan (Chairman), Mr. Stephane Bancel (CEO), and several independent directors, including Ms. Elizabeth Tallett and Dr. Robert Langer, among others. They are responsible for guiding the company's strategic direction and operations.
What does Moderna, Inc. do?
Moderna, Inc. is a large-cap biotechnology company focused on transformative medicines using mRNA technology. As of March 2025, it reported net sales of $108 million and a net loss of $971 million, with a market cap of approximately $9.88 billion.
How big is Moderna, Inc.?
As of Jun 18, Moderna, Inc. has a market capitalization of $9.88 billion, with recent net sales of $3.18 billion and a net profit of -$3.36 billion. Shareholder's funds are $10.90 billion, and total assets are $14.14 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
